KINGSTON, ON, Canada, March 16 /PRNewswire/ -- Millenium Biologix Inc. is very pleased to announce the appointment of Ian Malone to the position of Chief Financial Officer.
Ian is a former international banker and seasoned financial executive with extensive experience in the Canadian and International equity and debt markets. He will be responsible for all aspects of Corporate Finance and Administration.
“We are delighted to welcome Ian Malone to Millenium’s top management team at this pivotal time in the company’s development,” said Sydney Pugh, Chairman and CEO of Millenium Biologix. “As growth accelerates internationally, driven by the launch of exciting new product lines, additional corporate alliances, and selective vertical integration that will ensure optimum delivery of our premium products and unique brands into world markets, the need for reliable access to high quality capital is vital. Ian brings great experience, a record of success, and a reputation for excellence in this field, as well as important practical awareness of the real life operating needs present in a fast growing biomedical business. His will be a major contribution to leadership, growth, and new wealth creation at the company.”
Millenium Biologix Inc. is a leader in developing and supplying innovative products in the field of skeletal disease and trauma for clinical and research markets around the world. Founded on two revolutionary “core” technologies comprising Skelite(TM) biomaterials and synthesized Bone and Cartilage Stimulating Peptides (BCSP(TM)) growth factors, Millenium’s clinical market focus in regenerative medicine is the repair and replacement of skeletal tissues, including in vitro tissue engineering of autologous cartilage and bone.
Millenium Biologix Inc.
CONTACT: Inquiries should be directed to: Sheema Inayatulla,Communications Coordinator, Millenium Biologix Inc., 785 MidparkDrive, Kingston, Ontario, CANADA, K7M 7G3, T: 613.389.6565, F: 613.389.6625,E: info@millenium-biologix.com, http://www.millenium-biologix.com/
